Corium International, Inc. (NASDAQ:CORI) was downgraded by BidaskClub from a “strong-buy” rating to a “buy” rating in a report released on Tuesday, July 25th.
Other equities analysts have also issued reports about the stock. Needham & Company LLC reissued a “buy” rating and issued a $10.00 target price on shares of Corium International in a report on Friday, April 14th. Zacks Investment Research raised shares of Corium International from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a report on Friday, April 21st. Jefferies Group LLC set a $8.00 target price on shares of Corium International and gave the company a “buy” rating in a report on Thursday, April 20th. WBB Securities raised shares of Corium International to a “buy” rating and set a $13.00 price target on the stock in a report on Friday, July 7th. Finally, ValuEngine raised shares of Corium International from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $11.50.
Shares of Corium International (NASDAQ CORI) traded down 1.14% during trading on Tuesday, reaching $7.81. 283,087 shares of the company’s stock were exchanged. Corium International has a 52-week low of $2.67 and a 52-week high of $9.57. The company has a 50 day moving average price of $8.17 and a 200-day moving average price of $5.48. The company’s market capitalization is $228.30 million.
Corium International (NASDAQ:CORI) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by $0.13. Corium International had a negative return on equity of 1,550.00% and a negative net margin of 145.60%. The business had revenue of $8.11 million for the quarter, compared to the consensus estimate of $8.71 million. On average, equities analysts forecast that Corium International will post ($1.62) earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: “Corium International, Inc. (NASDAQ:CORI) Downgraded by BidaskClub to Buy” was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://stocknewstimes.com/2017/08/06/corium-international-inc-nasdaqcori-cut-to-buy-at-bidaskclub-updated.html.
In related news, major shareholder Perceptive Advisors Llc bought 1,902,400 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The shares were bought at an average price of $6.25 per share, for a total transaction of $11,890,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Life Sciences Maste Perceptive bought 301,004 shares of the company’s stock in a transaction that occurred on Friday, June 30th. The shares were bought at an average price of $7.71 per share, for a total transaction of $2,320,740.84. The disclosure for this purchase can be found here. 46.50% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp increased its position in Corium International by 161.8% in the second quarter. Bank of New York Mellon Corp now owns 66,160 shares of the biopharmaceutical company’s stock worth $494,000 after buying an additional 40,891 shares during the last quarter. Perceptive Advisors LLC bought a new position in Corium International during the first quarter worth about $11,096,000. Broadfin Capital LLC increased its position in Corium International by 45.2% in the first quarter. Broadfin Capital LLC now owns 2,787,121 shares of the biopharmaceutical company’s stock worth $11,650,000 after buying an additional 867,400 shares during the last quarter. AWM Investment Company Inc. increased its position in Corium International by 1,125.9% in the first quarter. AWM Investment Company Inc. now owns 2,451,700 shares of the biopharmaceutical company’s stock worth $10,248,000 after buying an additional 2,251,700 shares during the last quarter. Finally, Royce & Associates LP raised its stake in shares of Corium International by 208.4% in the first quarter. Royce & Associates LP now owns 548,464 shares of the biopharmaceutical company’s stock worth $2,293,000 after buying an additional 370,600 shares during the period. Institutional investors own 77.47% of the company’s stock.
About Corium International
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
